How can pharma teams validate AI in GxP environments—while accelerating innovation? AI has already enabled breakthroughs in personalized medicine, clinical trials, pharmacovigilance, and manufacturing. But when it comes to compliance, most pharma and biotech teams are still trying to validate AI models with tools built for deterministic software. This results in slower innovation, compliance gaps, and risky audit trails. Join Erez Kaminski, former head of AI at Amgen, and Gabriel Pascualy, former leader in Quality/Reliability for AI at Amgen, on Tuesday, April 22 at 11 AM ET for an expert-led webinar where you’ll learn: ✅ A step-by-step framework for AI validation in GxP-regulated environments ✅ Risk-based approaches to managing AI bias, explainability, and traceability ✅ Tools and automation strategies to streamline validation and regulatory approval ✅ How to align AI governance with FDA, EMA, and evolving compliance standards If you’re working on AI in pharma or biotech, this is a must-attend! #Pharma #AIValidation #GxP #Compliance #LLM #Biotech #Regulatory #Ketryx
This content isn’t available here
Access this content and more in the LinkedIn app